CORRECTING and REPLACING Pharmacyclics/Janssen Biotech’s PCI-32765 Has Earned Decision Resources’ Proprietary Clinical Gold Standard Status for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

BURLINGTON, Mass.--(BUSINESS WIRE)--Fourth graph, last sentence should read: ... but immunomodulatory agents—specifically Celgene’s Revlimid—and PCI-32765 will also capture significant patient share and sales. The corrected release reads: PHARMACYCLICS/JANSSEN BIOTECH’S PCI-32765 HAS EARNED DECISION RESOURCES’ PROPRIETARY CLINICAL GOLD STANDARD STATUS FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PCI-32765 Will Displace the Current Proprietary Clinical Gold Standard for

Feed Date: 
February 16, 2012